(4R,4aR,7S,7aR,12bS)-3,6-dimethyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (4R,4aR,7S,7aR,12bS)-3,6-dimethyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
• 化学式: C₁₈H₂₁NO₃
• 分子量: 299.4
• InChiKey: XPNQFJCQYHMGGC-LTHWPDAASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  52.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Abuse resistant capsule
  申请人：R.P. Scherer Technologies, LLC

  公开号：US10420729B2

  公开（公告）日：2019-09-24

  The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.

  本发明涉及一种速释和缓释胶囊或胶囊填充剂，它可减少通过直接静脉注射滥用易滥用的活性药物成分。填充物包括一种肠外抗滥用液体制剂，当与水混合并加热时，会产生一种浑浊、粘稠或起泡的混合物，不能用标准胰岛素注射器注射。抗滥用活性药物成分选自阿片类、阿片类、镇静剂、兴奋剂和麻醉剂。
• ABUSE RESISTANT CAPSULE
  申请人：R.P. Scherer Technologies, LLC

  公开号：EP2968129A1

  公开（公告）日：2016-01-20
• EP3446681B1
  申请人：——

  公开号：EP3446681B1

  公开（公告）日：2020-12-23
• US20140271835A1
  申请人：——

  公开号：US20140271835A1

  公开（公告）日：2014-09-18
• [EN] ABUSE RESISTANT CAPSULE<br/>[FR] CAPSULE RÉSISTANTE AUX ABUS
  申请人：WENGNER SIMONE

  公开号：WO2014140231A1

  公开（公告）日：2014-09-18

  The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.